Trial Profile
Phase 1 &2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; VEGFR-1 peptide vaccine (Primary) ; VEGFR-2 peptide vaccine (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Aug 2012 Actual end date (1 Mar 2012) added as reported by University Hospital Medical Information Network - Japan.
- 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 10 Feb 2011 New trial record